MSF finds J&J ’s darunavir patent relaxation plan selective
This article was originally published in Scrip
Executive Summary
Médecins Sans Frontières claims that Johnson and Johnson’s (J&J) recent announcement that in selective territories it would not assert it patents on its HIV/AIDS drug, darunavir, is limited in scope and ignores many countries where the company has patents for the drug.